

might provide a new method for treatment of osteoporosis, arthritis, cardiac diseases, and degenerative nerve diseases. Considering these findings,⁹⁻¹⁵ it is conceivable that MSCs might be useful for periodontal tissue regeneration. We previously developed a new culture system with fibroblast growth factor-2 (FGF-2) to expand MSCs with their multilineage differentiation potential.¹⁵ The purpose of the present study was to evaluate the potential of bone marrow mesenchymal stem cells, expanded by the culture system, on periodontal tissue regeneration *in vivo*.

MATERIALS AND METHODS

After receiving approval from the Committee of Research Facilities for Laboratory Animal Science, Hiroshima University School of Medicine, 12 female beagle dogs weighing 10 to 14 kg and aged 12 to 20 months were used in this study. Good oral health was established by scaling and mechanical toothbrushing.

Isolation and Development of Bone Marrow MSCs

Bone marrow aspirates of 1 ml were taken from the iliac crest of each animal under sodium pentobarbital (40 mg/kg) anesthesia. Cell culture was performed in accordance with the technique described by Tsutsumi et al.¹⁵ The cells, including erythrocytes, were seeded at 2×10^8 cells/100 mm in tissue culture dishes and maintained in 10 ml of Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum,[§] 0.05 unit/ml penicillin,^{||} and 0.05 mg/ml streptomycin.^{||} Three days after seeding, floating cells were removed and the medium was replaced with fresh medium. Thereafter, attached cells were fed with fresh medium every 3 days. Passages were performed when cells were approaching confluence. Cells were seeded at 5×10^3 cells/cm² in 100 mm dishes and maintained in the medium containing 3 ng/ml FGF-2[¶] for 2 weeks. The cells were harvested with trypsin plus EDTA, washed with phosphate buffered saline, and stored in liquid nitrogen until use. In this study, cell passage 3 was used for transplantation.

Creation of Class III Furcation Defects and Transplantation of MSCs

All surgical procedures were performed under general anesthesia with sodium pentobarbital (40 mg/kg), and local infiltrated anesthesia with 2% lidocaine with 1:80,000 noradrenaline. Experimental Class III furcation defects prepared in this study were based on the model described by Lindhe et al.¹⁶ The second, third, and fourth




Figure 1.

Presurgical view of the mandibular premolar area (A); after defect preparation (B); after transplantation of various concentrations of MSCs in atelocollagen (C); after repositioning of gingival flaps and suturing (D).

premolars (P2, P3, and P4) in each dog were selected for experimentation (Fig. 1). Following sulcular incisions, mucoperiosteal flaps were raised, and Class III furcation defects were created surgically at P2, P3, and P4. The Class III defect height from the cemento-enamel junction to the reduced alveolar crest was 4 mm. Denuded root surfaces were prepared to remove all periodontal ligament and cementum. The roots were denuded only in the area within the furcation and extending to the mesial line angle for the mesial root and to the distal line angle for the distal root. Reference notches were placed around the circumference of the mesial and distal roots at the bottom of the bone level.

The MSCs cultured for 2 weeks were suspended, and four groups of MSC-collagen gel material were prepared. That is, 2×10^6 , 5×10^6 , 1×10^7 , and 2×10^7 MSCs were mixed with 1 ml of atelocollagen (2% type I collagen extracted from bovine calf skin by pepsin digestion).[#] All four groups of the MSC-collagen gel and the atelocollagen alone were transplanted into the Class III furcations in all 12 dogs. The flaps were coronally repositioned and sutured with 4-0 interrupted silk sutures. Good oral hygiene was maintained postoperatively by brushing and swabbing with 0.2% povidone iodine.^{**}

Tissue Preparation for Histological Analysis

One month after transplantation, anesthetized animals were perfused with 1% glutaraldehyde in sodium cacodylate buffer containing 0.05% calcium chloride (pH 7.3).

§ Hyclone, South Logan, UT.

|| Invitrogen Corp., Carlsbad, CA.

¶ PeproTech EC Ltd., Rocky Hill, NJ.

Koken Co., Ltd., Tokyo, Japan.

** Meiji-seika Co., Ltd., Tokyo, Japan.




Figure 2. Schematic drawing of morphometric analysis of percentage of new cementum length and percentage of new bone area.

The mandibles were dissected and immersed in the same fixative. After decalcification with hydrochloride for 3 to 5 days, the mandibles were dehydrated through graded ethanol, cleared with xylene, and embedded in paraffin. Serial sections (5 μm) were cut in the mesial-distal plane throughout the buccal-lingal extension of the tooth. The sections were stained with hematoxylin and eosin (H&E) or the Azan method, and observed using a light microscope. The most central section and the immediate section on either side were subjected to morphometric analysis.

Morphometric Analysis

The percentage of new cementum length and percentage of new bone area were measured on digitized photomicrographs captured in a computer. The lengths of new cementum formed along the denuded root surface on each specimen were added, and the percentage of the lengths to the total root surface length from one notch to the next notch was calculated. The area of new bone on each specimen was calculated as a percentage of the area surrounded with reference notches at mesial and distal root surfaces facing the bone defect. Since the periodontal ligament space is present in normal periodontal tissue, the percentage of bone area in untreated specimens was also calculated (Fig. 2). All data were statistically analyzed using the Mann-Whitney U test.

RESULTS

In the MSC-atelocollagen groups (experimental groups), significant amounts of new bone and adequate width of periodontal ligament were observed (Fig. 3). The denuded root surface was almost completely covered with new cementum, and regenerated periodontal ligament separated the new bone from the cementum (Fig. 4). On the denuded root surfaces of the furcation area, newly formed cementum covered the surface, and Sharpey's fibers inserted into the cementum were frequently observed (Fig. 5). However, complete alveolar




Figure 3. Low-power view of Class III defects in the mesio-distal plane 1 month after transplantation of MSCs (2 × 10⁷ cells/ml) in atelocollagen. Significant amounts of new bone and cementum, and adequate width of periodontal ligament can be observed. Arrows indicate apical border of the denuded root surface. The square area is shown in higher magnification in Figure 4. (H&E staining; bar = 200 μm.)




Figure 4. A higher-power view of the square area in Figure 3 showing new cementum (C), bone (B), and regenerated periodontal ligament (PDL). (H&E staining; bar = 20 μm.)

bone reconstruction was not obtained. Epithelial cell invasion, bone ankylosis, and root resorption were not observed on the root surface. In the atelocollagen alone



Figure 5. A higher-power view of the furcation area in Figure 3 showing new cementum with Sharpey's fibers. (Azan staining; bar = 20 μ m.)



Figure 6. Low-power view of Class III defect in the mesio-distal plane 1 month after implantation of atelocollagen alone. Migration of epithelial cells into the top of the furcation and cementum formation were not observed in the area. Note less bone regeneration compared to Figure 3. Arrows indicate apical border of denuded root surface. (H&E staining; bar = 200 μ m.)




Figure 7. The percentage of new cementum length. The 5×10^6 and 2×10^7 cells/ml groups were significantly higher compared to the control group (* $P < 0.01$).

group (control group), epithelial cells invaded into the top of the furcation, and no cementum regeneration was observed in the area (Fig. 6). Less bone regeneration was observed in this group compared to the MSC-atelocollagen groups. Bone ankylosis and root resorption were not observed.

The percentages of new cementum length in the 2×10^6 , 5×10^6 , 1×10^7 , and 2×10^7 cells/ml groups were $93.9 \pm 14.3\%$, $96.7 \pm 5.23\%$, $91.3 \pm 12.3\%$, and $94.4 \pm 8.27\%$, respectively, compared to $70.5 \pm 12.0\%$ in the control group (Fig. 7). However, a significant difference was observed only in the 5×10^6 and




Figure 8. The percentage of new bone area. The 2×10^7 cells/ml group was significantly higher compared to the control group (* $P < 0.01$).

2×10^7 cells/ml groups ($P < 0.01$). The percentages of new bone area in the experimental groups were $62.6 \pm 14.6\%$, $62.5 \pm 13.6\%$, $65.8 \pm 9.62\%$, and $68.1 \pm 10.7\%$, respectively, compared to $54.8 \pm 10.7\%$ in the control group (Fig. 8). In particular, the percent-

age of new bone area in the 2×10^7 cells/ml group was significantly ($P < 0.01$) higher than in the control group. The percentage of bone area in the normal specimen was 73%.

DISCUSSION

The findings of this study suggest that auto-transplantation of bone marrow mesenchymal stem cells can promote periodontal tissue regeneration. We speculate that this was not solely due to stimulated regeneration from resident cells. It was reported that bone marrow MSCs can be induced to differentiate into osteoblasts, chondrocytes, tenocytes, adipocytes, etc.⁹⁻¹⁵ If tissue regeneration can be accomplished by a single cell type, as in the case of bone or cartilage defects, transplantation of MSC-derived osteoblasts or chondrocytes may be effective. To promote chondrogenic differentiation, MSCs were cultured without serum and with transforming growth factor- $\beta 3$.⁹ To promote osteogenic differentiation, MSCs were cultured with dexamethasone, β -glycerophosphate, and ascorbate in the presence of 10% v/v fetal bovine serum.¹⁰ However, plural cell types, including cementoblasts, osteoblasts, and periodontal ligament fibroblasts, were required for periodontal tissue regeneration. Recent studies reported that transplanted bone marrow MSCs differentiated into various connective tissue cells in vivo under the influence of host factors.^{17,18} It was also proposed that injured tissues produce the appropriate cues necessary for engraftment. Thereafter, the local microenvironment stimulates the differentiation of transplanted cells into functional, specialized cells.¹⁹ The findings in the current study showed that reconstruction of periodontal tissue, cementum, alveolar bone, and periodontal ligament occurred after bone marrow MSCs were transplanted into Class III defects. Although we do not know the precise mechanisms underlying periodontal tissue regeneration with MSCs, it might be possible that transplanted bone marrow MSCs expressed their multilineage differentiation potential in vivo and underwent site-specific differentiation into the appropriate periodontal cells. Thus, periodontal regeneration may have been accomplished by transplantation of bone marrow MSCs that had not received preinduction or treatment for differentiation.

One significant finding of this study was that cementum with extrinsic fibers formed along almost all of the denuded root surfaces after MSC transplantation. Previous studies showed that new cementum had increased thickness, greater cellularity, a predominance of intrinsic collagen fibers, and the investment of sparse, extrinsic Sharpey's fibers.²⁰⁻²⁵ However, some histological studies showed that enamel matrix derivative (EMD) treatment and combined treatment with EMD and GTR induced the formation of an acellular type of cementum.²⁶⁻³¹ Discrepancies in these histological findings on cementum may reflect heterogeneity in both cellular activity and extracellular

matrix events during periodontal healing. Tissue dynamics must be considered to understand these variations.

Once new cementum with extrinsic fibers covers the denuded root surface, epithelial cells may not be able to migrate on the surface. It has been hypothesized that the type of tissue which predominates in the healing wound determines whether the response is one of repair or regeneration.³² Moreover, components of newly formed cementum matrix provide informational signals for recruitment, proliferation, and differentiation of periodontal cells and regulate regeneration of cementum in addition to adjacent periodontal components.³³ It is generally accepted that new cementum formation and restoration of soft tissue attachment to the cementum are the major goal of regenerative periodontal therapy.^{1,4,33} Therefore, MSC transplantation may be useful for periodontal tissue regeneration.

The amount of regeneration observed in the control group was still quite significant, although admittedly less organized than that observed in the MSC-Atelocollagen groups. In this study, experimental defects were treated immediately. It has been reported that approximately 50% to 70% spontaneous regeneration can be expected in acute defect models.³⁴ Subsequent studies of MSC transplantation into a chronic, plaque-infected periodontal defect model and/or a large periodontal defect model would provide further information on periodontal regeneration.

Although the mechanism by which MSC transplantation induces formation of cementum is unknown, MSCs may attach to denuded root surfaces and cell-matrix interactions may promote their differentiation. A variety of chemotactic factors, adhesion molecules, growth factors, and extracellular matrix macromolecules could participate together in inducing differentiation of MSCs into cementoblasts or could recruit cementoblast progenitors.³³ A previous study showed deposition of cementum-like matrix when periodontal ligament cells were cultured on the root surface.³⁵ Thus, the local environment is an important regulator of cell activity.

We used atelocollagen as a biomaterial scaffold to hold MSCs in a temporary matrix, and to keep them suspended during transplantation and in the early period of regeneration. When considering clinical applications, a safe scaffold must be carefully selected. With atelocollagen, the antigenic determinants on the peptide chain of type I collagen (telopeptide) are removed, and thus it is often used clinically for the treatment of skin disorders.^{36,37} Furthermore, autologous chondrocytes embedded in atelocollagen transplanted into cartilage defects were reported to promote repair.³⁸⁻⁴⁰ Accordingly, atelocollagen is an appropriate scaffold material for MSC transplantation.

Cell density of MSCs is also an important factor for tissue regeneration. Sufficient tissue fluids and blood supply might be necessary for MSCs to survive after

transplantation and subsequent differentiation into periodontal cells. A high cell concentration of MSCs might disturb the infiltration of nutrients into the deeper areas of transplanted MSCs. Among the cell concentrations (2×10^6 to 2×10^7) used in the present study, no significant differences were observed in bone or cementum formation. Effective tissue regeneration was reported when the same range of cell concentrations was used for transplantation into various defects.³⁹⁻⁴³ However, additional studies with different scaffold materials and various concentrations of cells will extend our knowledge on viable periodontal tissue engineering.

Polypeptide growth factors, including platelet-derived growth factor (PDGF), insulin-like growth factor (IGF), transforming growth factor (TGF), fibroblast growth factor (FGF), and bone morphogenetic protein (BMP), have been applied to periodontal defects.⁴ In vivo and in vitro studies suggested that FGF, PDGF, and PDGF combined with IGF strongly stimulate periodontal tissue regeneration.⁴⁴⁻⁴⁷ BMP has the potential for stimulating bone and cementum regeneration.^{48,49} A human clinical trial in 1997 tested the safety and efficacy of several of these growth factors in the treatment of periodontal defects.⁵⁰ In the future, transplantation of MSCs with these growth factors will likely have even better beneficial effects on periodontal tissue regeneration. Growth factors play different roles depending upon the healing stage, target cells, and availability of matrix components.⁴ The actions of these growth factors on residual periodontal cells and transplanted MSCs remain unknown.

In conclusion, the present findings suggest that autotransplantation of bone marrow MSCs is a useful option for periodontal tissue regeneration. Our culture system to expand bone marrow MSCs decreased the volume of bone marrow aspirates.¹⁵

ACKNOWLEDGMENTS

The authors are grateful to Drs. K. Matsubara, T. Koike, S. Tsutsumi, K. Miyazaki, and H. Pan for their excellent technical support, and to Drs. M. Miyauchi and S. Kitagawa for the histological preparations. We also thank Dr. K. Tsuji, Two Cells Co., Ltd., Hiroshima, Japan, for comments and discussions on the manuscript. This study was supported by a Grant-in-Aid for Scientific Research (no. 13470464).

REFERENCES

1. Karring T, Nyman S, Gottlow J, Laurell L. Development of the biological concept of guided tissue regeneration—animal and human studies. *Periodontol 2000* 1993;1:26-35.
2. Cortellini P, Tonetti MS. Focus on infrabony defects: Guided tissue regeneration. *Periodontol 2000* 2000;22:104-132.
3. Sanz M, Giovannoli JL. Focus on furcation defects: Guided tissue regeneration. *Periodontol 2000* 2000;24:253-269.
4. Bartold PM, McCulloch CAG, Narayanan AS, Pitaru S. Tissue engineering: A new paradigm for periodontal regeneration based on molecular and cell biology. *Periodontol 2000* 2000;22:169-189.
5. Kalpidis CD, Ruben MP. Treatment of intrabony periodontal defects with enamel matrix derivative: A literature review. *J Periodontol* 2002;73:1360-1376.
6. Karring T. Regenerative periodontal therapy. *J Int Acad Periodontol* 2000;2:101-109.
7. Froum SJ, Gomez C, Breault MR. Current concepts of periodontal regeneration. A review of the literature. *NY State Dent J* 2002;68:14-22.
8. Langer R, Vacanti JP. Tissue engineering. *Science* 1993;260:920-926.
9. Bruder SP, Jaiswal N, Haynesworth SE. Growth kinetics, self-renewal, and the osteogenic potential of purified human mesenchymal stem cells during extensive subcultivation and following cryopreservation. *J Cell Biochem* 1997;64:278-294.
10. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. *Science* 1999;284:143-147.
11. Kuznetsov SA, Mankani MH, Gronthos S, Satomura K, Bianco P, Robey PG. Circulating skeletal stem cells. *J Cell Biol* 2001;153:1133-1140.
12. Makino S, Fukuda K, Miyoshi S, et al. Cardiomyocytes can be generated from marrow stromal cells in vitro. *J Clin Invest* 1999;103:697-705.
13. Deans RJ, Moseley AB. Mesenchymal stem cells: Biology and potential clinical use. *Exp Hematol* 2000;28:875-884.
14. Kopen GC, Prockop DJ, Phinney DG. Marrow stromal cells migrate throughout forebrain and cerebellum, and they differentiate into astrocytes after injection into neonatal mouse brains. *Proc Natl Acad Sci (USA)* 1999;96:10711-10716.
15. Tsutsumi S, Shimazu A, Miyazaki K, et al. Retention of multilineage differentiation potential of mesenchymal cells during proliferation in response to FGF. *Biochem Biophys Res Commun* 2001;288:413-419.
16. Lindhe J, Pontoriero R, Berglundh T, Araujo M. The effect of flap management and bioresorbable occlusive devices in GTR treatment of degree III furcation defects. An experimental study in dogs. *J Clin Periodontol* 1995;22:276-283.
17. Liechty KW, MacKenzie TC, Shaaban AF, et al. Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep. *Nat Med* 2000;6:1282-1286.
18. Quintavalla J, Uziel-Fusi S, Yin J, et al. Fluorescently labeled mesenchymal stem cells (MSCs) maintain multilineage potential and can be detected following implantation into articular cartilage defects. *Biomaterials* 2002;23:109-119.
19. Krause DS, Theise ND, Collector MI, et al. Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell. *Cell* 2001;105:369-377.
20. Listgarten MA. Electron microscopic study of the junction between surgically denuded root surfaces and regenerated periodontal tissue. *J Periodontol Res* 1972;7:68-90.
21. Frank R, Fiore-Donno G, Cimasoni G, Matter J. Ultrastructural study of epithelial and connective gingival reattachment in man. *J Periodontol* 1974;45:626-635.
22. Bowers GM, Chadroff B, Carnevale R, et al. Histologic evaluation of new attachment apparatus formation in humans. Part III. *J Periodontol* 1989;60:683-693.
23. Ten Cate AR. The development of periodontium – a largely ectomesenchymally derived unit. *Periodontol 2000* 1997;13:9-19.
24. Araujo M, Berglundh T, Lindhe J. The periodontal tissues

- in healed degree III furcation defects. An experimental study in dogs. *J Clin Periodontol* 1996;23:532-541.
25. Ripamonti U, Heliotis M, Rueger DC, Sampath TK. Induction of cementogenesis by recombinant human osteogenic protein-1 (hOP-1/BMP-7) in the baboon (*Papio ursinus*). *Arch Oral Biol* 1996;41:121-126.
 26. Hammarstrom L. Enamel matrix, cementum development and regeneration. *J Clin Periodontol* 1997;24:658-668.
 27. Hammarstrom L, Heijl L, Gestrelus S. Periodontal regeneration in a buccal dehiscence model in monkeys after application of enamel matrix proteins. *J Clin Periodontol* 1997;24:669-677.
 28. Heijl L. Periodontal regeneration with enamel matrix derivative in one human experimental defect. A case report. *J Clin Periodontol* 1997;24:693-696.
 29. Mellonig JT. Enamel matrix derivative for periodontal reconstructive surgery: Technique and clinical and histologic case report. *Int J Periodontics Restorative Dent* 1999;19:8-19.
 30. Araujo MG, Lindhe J. GTR treatment of degree III furcation defects following application of enamel matrix proteins. An experimental study in dogs. *J Clin Periodontol* 1998;25:524-530.
 31. Sculean A, Donos N, Brex M, Reich E, Karring T. Treatment of intrabony defects with guided tissue regeneration and enamel matrix proteins. An experimental study in monkeys. *J Clin Periodontol* 2000;27:466-472.
 32. Melcher AH. On the repair potential of periodontal tissues. *J Periodontol* 1976;47:256-260.
 33. Grzesik WJ, Narayanan AS. Cementum and periodontal wound healing and regeneration. *Crit Rev Oral Biol Med* 2002;13:474-484.
 34. Caton J, Mota L, Gandini L, Laskaris B. Non-human primate models for testing the efficacy and safety of periodontal regeneration procedures. *J Periodontol* 1994;65:1143-1150.
 35. BarKana I, Narayanan AS, Roskopf A, Savion N, Pitaru S. Cementum attachment protein enriches putative cementoblastic populations on root surfaces in vitro. *J Dent Res* 2000;79:1482-1488.
 36. Charriere G, Bejot M, Schnitzler L, Ville G, Hartmann DJ. Reactions to a bovine collagen implant. Clinical and immunologic study in 705 patients. *J Am Acad Dermatol* 1989;21:1203-1208.
 37. Yamada N, Uchinuma E, Kuroyanagi Y. Clinical evaluation of an allogeneic cultured dermal substitute composed of fibroblasts within a spongy collagen matrix. *Scand J Plast Reconstr Surg Hand Surg* 1999;33:147-154.
 38. Katsube K, Ochi M, Uchio Y, et al. Repair of articular cartilage defects with cultured chondrocytes in Atelocollagen gel. *Arch Orthop Trauma Surg* 2000;120:121-127.
 39. Ochi M, Uchio Y, Tobita M, Kuriwaka M. Current concepts in tissue engineering technique for repair of cartilage defect. *Artif Organs* 2001;25:172-179.
 40. Ochi M, Uchio Y, Kawasaki K, Wakitani S, Iwasa J. Transplantation of cartilage-like tissue made by tissue engineering in the treatment of cartilage defects of the knee. *J Bone Joint Surg Br* 2002;84:571-578.
 41. Awad HA, Butler DL, Harris MT. In vitro characterization of mesenchymal stem cell-seeded collagen scaffolds for tendon repair: Effects of initial seeding density on contraction kinetics. *J Biomed Mater Res* 2000;51:233-240.
 42. Iwasa J, Ochi M, Uchio Y, Katsube K, Adachi N, Kawasaki K. Effects of cell density on proliferation and matrix synthesis of chondrocytes embedded in atelocollagen gel. *Artif Organs* 2003;27:249-255.
 43. Sakai D, Mochida J, Yamamoto Y. Transplantation of mesenchymal stem cells embedded in Atelocollagen gel to the intervertebral disc: A potential therapeutic model for disc degeneration. *Biomaterials* 2003;24:3531-3541.
 44. Lynch SE, de Castilla RG, Williams RC, et al. The effects of short-term application of a combination of platelet-derived and insulin-like growth factors on periodontal wound healing. *J Periodontol* 1991;62:458-467.
 45. Rutherford RB, Ryan ME, Kennedy JE, Tucker MM, Charette MF. Platelet-derived growth factor and dexamethasone combined with a collagen matrix induce regeneration of the periodontium in monkeys. *J Clin Periodontol* 1993;20:537-544.
 46. Murakami S, Takayama S, Ikezawa K, et al. Regeneration of periodontal tissues by basic fibroblast growth factor. *J Periodontol Res* 1999;34:425-430.
 47. Murakami S, Takayama S, Kitamura M, et al. Recombinant human basic fibroblast growth factor (bFGF) stimulates periodontal regeneration in class II furcation defects created in beagle dogs. *J Periodontol Res* 2003;38:97-103.
 48. Kuboki Y, Sasaki M, Saito A, Takita H, Kato H. Regeneration of periodontal ligament and cementum by BMP-applied tissue engineering. *Eur J Oral Sci* 1998;106:197-203.
 49. Ripamonti U, Reddi AH. Periodontal regeneration: Potential role of bone morphogenetic proteins. *J Periodontol Res* 1994;29:225-235.
 50. Howell TH, Fiorellini JP, Paquette DW, Offenbacher S, Giannobile WV, Lynch SE. A phase I/II clinical trial to evaluate a combination of recombinant human platelet-derived growth factor-I in patients with periodontal disease. *J Periodontol* 1997;68:1186-1193.

Correspondence: Dr. Hiroyuki Kawaguchi, Department of Periodontal Medicine, Division of Frontier Medical Science, Hiroshima University Graduate School of Biomedical Sciences, 1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8553, Japan. E-mail: hkawa@hiroshima-u.ac.jp.

Accepted for publication January 23, 2004.

STEM CELLS®

Original Article

Enforced Expression of PU.1 Rescues Osteoclastogenesis from Embryonic Stem Cells Lacking Tal-1

MOTOKAZU TSUNETO,^a AKIRA TOMINAGA,^b HIDETOSHI YAMAZAKI,^{a,c} MIYA YOSHINO,^a
STUART H. ORKIN,^d SHIN-ICHI HAYASHI^a

^aDivision of Immunology, Department of Molecular and Cellular Biology, School of Life Science, Faculty of Medicine, Tottori University, Yonago, Tottori, Japan; ^bDepartment of Molecular and Cellular Biology, Kochi Medical School, and Laboratory of Human Health and Medical Science, Graduate School of Kuroshio Science, Nankoku, Kochi, Japan; ^cDivision of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University Graduate School of Medical Science, Yonago, Tottori, Japan.; ^dDepartment of Pediatric Oncology, Children's Hospital and the Dana Farber Cancer Institute, Harvard Medical School and Howard Hughes Medical Institute, Boston, Massachusetts, USA

Key Words. Embryonic stem cells • Hematopoiesis • PU.1 • Transcription factor SCL/Tal-1 • Osteoclast

ABSTRACT

Transcription factor T-cell acute lymphocytic leukemia 1 (Tal-1) is essential for the specification of hematopoietic development. Mice lacking *Tal1* fail to generate any hematopoietic precursors. Using our co-culture system with stromal cells, we demonstrate that enforced expression of the transcription factor PU.1 under tetracycline control in *Tal1*-null embryonic stem (ES) cells rescues the development of osteoclasts and macrophage-like phagocytes. It was low efficiency compared with wild-type ES cells; other hematopoietic lineage cells of granulocytes, B cells, mast cells, megakaryocytes, and erythroid cells

were not generated. Osteoclasts developed in this culture were multinucleated and competent for bone resorption. Their development depended on macrophage colony-stimulating factor and receptor activator of nuclear factor κ B ligand. The majority of cells with the potential to differentiate into osteoclasts expressed fetal liver kinase 1 (Flk-1) and could be isolated using anti-Flk-1 antibody. These results suggest that the expression of PU.1 is a critical event for osteoclastogenesis and that Tal-1 may lie upstream of PU.1 in a regulatory hierarchy during osteoclastogenesis. *STEM CELLS* 2005;23:134–143

INTRODUCTION

Hematopoiesis can be viewed as a hierarchy with hematopoietic stem cells (HSCs) at the top and progenitors and their descendents below. *Tal1* gene knockout (*Tal1*^{-/-}) mice succumb during embryogenesis due to a complete failure to produce blood cells [1, 2]. The product of the *Tal1* gene is

believed to be essential for the initiation of hematopoietic development and the formation of HSCs. Consistent with the absence of hematopoietic cells and their descendents, transcription factor PU.1 (gene symbol, *Sfp1*) is not detected in *Tal1*^{-/-} embryonic stem (ES) cells induced to form hematopoietic cells in vitro [3] (in this report). PU.1

Correspondence: Motokazu Tsuneto, Ph.D., Division of Immunology, Department of Molecular and Cellular Biology, School of Life Science, Faculty of Medicine, Tottori University, 86 Nishi-Machi, Yonago, Tottori, 683-8503, Japan. Telephone: 81-859-34-8270; Fax: 81-859-34-8272; e-mail: tsune13@grape.med.tottori-u.ac.jp Received July 8, 2004; accepted for publication August 24, 2004. ©AlphaMed Press 1066-5099/2005/\$12.00/0 doi: 10.1634/stemcells.2004-0154

controls development into myeloid and B-lymphoid cell lineages by regulating, in part, the receptors for macrophage colony-stimulating factor (M-CSF), Fms [4], and interleukin-7 (IL-7R) α [5], respectively. Myelopoiesis, B lymphopoiesis, and osteoclastogenesis are impaired in PU.1-deficient mice [6, 7]. Therefore, although it is not clear whether the expression of PU.1 is directly regulated by Tal-1, we wondered whether deficiency of Tal-1 might lead to failure to induce PU.1, resulting in the absence of some (or all) PU.1-dependent lineages.

Osteoclasts resorb bone matrices. They are ultimately derived from HSCs. Osteoclasts are distinguished by their multinuclearity and expression of tartrate-resistant acid phosphatase (TRAP) [8–10]. Osteoblasts and stromal cells support osteoclastogenesis by supplying essential factors, such as M-CSF [11] and receptor activator of nuclear factor κ B ligand (RANKL) [12–14]. Previously we developed a culture system for osteoclastogenesis in which ES cells are co-cultured with stromal cells [15]. This system enables access to the entire program of osteoclastogenesis from undifferentiated ES cells to mature functional osteoclasts.

To assess the potential function of PU.1 downstream of Tal-1 in osteoclastogenesis, we have expressed exogenous PU.1 in *Tal1*^{-/-} ES cells using the tetracycline (Tc)-off system [16, 17]. Surprisingly, we observe that enforced PU.1 expression induced osteoclast differentiation, even though the efficiency was lower than in wild-type ES cells. In this context, osteoclast development depended on M-CSF and RANKL, as in normal osteoclastogenesis. These findings suggest that PU.1 is a critical transcription factor for osteoclastogenesis; they are consistent with a role for PU.1 downstream of Tal-1 in a pathway culminating in osteoclastogenesis.

MATERIALS AND METHODS

Cell Lines

A bone marrow-derived stromal cell line, ST2 [18], was maintained in RPMI-1640 (Roswell Park Memorial Institute: Gibco-Invitrogen Corp., Grand Island, NY; <http://www.invitrogen.com>), supplemented with 5×10^{-5} M 2-mercaptoethanol (2ME: Wako Pure Chemical Industries, Osaka, Japan; <http://www.wako-chem.co.jp/english>) and 5% fetal bovine serum (FBS: JRH Biosciences, Lenexa, KS; <http://www.jrhbio.com>). The OP9 stromal cell line [19] was cultured in minimum essential medium alpha (α MEM: Gibco-Invitrogen) supplemented with 20% FBS. ES cell lines J1 and *Tal1*^{-/-} J1 [2], and *Sfp1* PU1-transfected *Tal1*^{-/-} J1 ES cell lines were maintained in Dulbecco's modified essential medium (DMEM: Gibco-Invitrogen) supplemented with 10% knockout serum (Gibco-Invitrogen), 1% heat-inactivated FBS, 10^{-4} M 2ME, $1 \times$ nonessential amino acids (Gibco-Invitrogen), 2 mM L-

glutamine (Gibco-Invitrogen), and leukemia inhibitory factor (LIF) equivalent to 1,000 U/ml on 0.1% gelatin-coated culture dishes. The RAW 264.7 macrophage cell line was maintained in α MEM supplemented with 10% FBS (JRH).

Constructs

Tal1^{-/-} J1 ES cells were first transfected with Tc-regulated transactivator (tTA) driven by the CAG promoter [20] of the Tc-responsive promoter (CMV*-1)-puro' (a gift from Dr. H. Niwa, RIKEN Kobe, Japan). These cells were cultured in the presence of 1 μ g/ml puromycin and LIF for 8 days, and growing colonies were recovered. After Tc was added to the culture medium, clones sensitive to puromycin were chosen. These clones were secondarily transfected with a CMV*-1-ligated mouse *Sfp1* cDNA sequence, followed by an internal ribosomal entry site (IRES) and green fluorescent protein (GFP) (CMV*-1-PU.1-IRES-EGFP, Fig. 1A). PSV2-*bsr* was simultaneously transfected. These cells were cultured with 1 μ g/ml Tc and 3 μ g/ml blastocidin S hydrochloride (blastocidin: Kaken Pharmaceutical Co., Tokyo, Japan; <http://www.nni.nikkei.co.jp>) for an initial 4 days, and during the following period, 0.5 μ g/ml blastocidin was added to cultures. On day 12, colonies were picked up, and clones whose expression of GFP was regulated by Tc were chosen.

Differentiation of ES Cells

Undifferentiated ES cells were inoculated at 10^4 cells per well in six-well plates (Corning, NY; <http://www.corning.com>) on pre-seeded OP9 cells and cultivated in α MEM supplemented with 20% FBS (Thermo Trace, Melbourne, Australia; <http://www.thermotrace.com.au/>). On day 5, the cells were harvested and re-seeded at 10^5 cells per well in six-well plates onto confluent OP9 layers [19] in α MEM containing 20% FBS. Five days later, cells were harvested and osteoclasts were induced on ST2 stromal cells at 10^3 cells per 24-well plate (Corning) in α MEM/10% FBS (JRH) supplemented with 10^{-8} M $1\alpha,25(\text{OH})_2\text{D}_3$ (Biomol Research Laboratories, Plymouth Meeting, PA; <http://www.biomol.com>) and 10^{-7} M dexamethasone (Dex: Sigma Chemical Corp., St. Louis, MO; <http://www.sigma-aldrich.com>). Six days later, TRAP staining was performed and TRAP⁺ cells were counted under a microscope. These cultures are referred to as the osteoclast cultures (Fig. 1E) [21]. In the pit-formation assay, cells derived from ES cells were co-cultured with ST2 cells in the presence of 10^{-8} M $1\alpha,25(\text{OH})_2\text{D}_3$, 10^{-7} M Dex, 10 μ g/ml human M-CSF (provided by Dr. M. Takahashi, Otsuka Pharmaceutical, Tokyo), and 25 ng/ml human soluble RANKL (PeproTech, Rocky Hill, NJ; <http://www.peprotech.com>) on dentine slices (a gift from Dr. N. Udagawa, Matsumoto Dental University, Shiojiri, Japan).

Western Blot Analysis

Proteins were extracted from cultured cells by lysing the cells with lysis buffer containing EDTA and Triton X-100. Each sample (300 µg of protein) was separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a nitrocellulose membrane (Hybond ECL; Amersham Pharmacia Biotech, Piscataway, NJ; <http://www.amershambiosciences.com>). After the membrane was blocked with 5% skim milk (DIFCO Laboratories, Detroit, MI; <http://www.vgdusa.com/DIFCO.htm>), it was incubated with rabbit anti-mouse PU.1 antibody. PU.1 protein was visualized by using horseradish peroxidase (HRP)-conjugated goat anti-rabbit immunoglobulin-G (IgG) (Amersham Pharmacia Biotech) and the enhanced chemiluminescence (ECL) detection system (Amersham Pharmacia Biotech). Protein extract from macrophage cell line RAW264.7 was used as positive control.

TRAP Staining

Cultured cells were fixed with 10% formaldehyde (Wako Pure Chemical Industries) for 10 minutes at room temperature and with ethanol/acetone (50:50 v/v; Wako) for 1 minute. After the cells were washed with PBS, they were stained with fast red violet LB-salt (Sigma) mixed with TRAP solution containing 59.3 M of sodium tartrate (Wako), 165.7 M sodium acetate (Wako), and 0.56 mg/ml naphthol AS-MX phosphate (Sigma) for 5 minutes at room temperature. Red-stained cells were visualized under a microscope and counted as TRAP⁺ cells.

Reverse Transcription-Polymerase Chain Reaction (RT-PCR)

Total RNA was purified using ISOGEN (Nippon Gene, Toyama, Japan; www.nippongene.jp) and used as the template to synthesize cDNA using RevaTra Ace (Toyobo, Osaka, Japan; <http://www.toyobo.co.jp/e>) primed with oligo-dT from 1 µg of total RNA. Gene expression was analyzed by PCR using the following primers:

Tal1: 5'-CCT CCC CAT ATG AGA TGG AGA-3' and 5'-CCA TCC AGA GAG CTG CCA CA-3'

Both endogenous and exogenous *Sfp1*: 5'-GGA GAC AGG CAG CAA GAA AA-3' and 5'-GCG ACG GGT TAA TGC TAT GG-3'.

Only endogenous *Sfp1*: 5'-TTG ATC CCC ACC GAA GCA GG-3' and 5'-ATG TGG CGA TAG AGCTGCTG-3'

Hbb (b-hemoglobin): 5'-CAC AAC CCC AGA AAC AGA CA-3' and 5'-CTG ACA GAT GCT CTCTTG GG-3'

Hbb-bh1 (ζ-hemoglobin): 5'-GCT CAG GCC GAG CCC ATT GG-3' and 5'-TAG CGG TACTTCTCA GTC AG-3'

Pax5: 5'-CTA CAG GCT CCG TGA CGC AG-3' and 5'-TCT CGG CCT GTG ACA ATA GG-3'

Igb (Igβ/B29): 5'-GCA GCC CCA GGA ACT GGT CT-3' and 5'-CCT CCA TCC CAG CCT TGC CG-3'

Cpa3 (mast cell carboxypeptidase A precursors; mMC-CPA): 5'-CCG TGT GAA ACT CCA GAA TG-3' and 5'-GTG CAT GAA TGC CAC AGT CC-3'

Pbp (platelet basic protein; PBP): 5'-ATG GGC TTC AGA




Figure 1. Establishment of Tc-controlled PU.1-expressing *Tal1*^{-/-} ES cell lines. (A): Constructs transfected into *Tal1*^{-/-} ES cells (see Materials and Methods). (B, C): The expression of PU.1 was evaluated by monitoring the fluorescence of GFP. ES cells were cultured in the presence of LIF, and flow cytometric analysis was performed 1 or 2 days after Tc was withdrawn (B). Microscopic analysis of phase contrast field and fluorescent microscopic fields of TUNE ES cells cultured with TC (Tc+) or without Tc (Tc-) TC for 2 days in upper and lower rows, respectively (C). (D): PU.1 protein was detected in cell lysates prepared on day 2 or day 3 from TUNE ES cells cultured on OP9 cells after Tc was withdrawn starting on day 0, and from a macrophage cell line, RAW264.7 (RAW). Cell lysates from TUNE ES cells cultured in the presence of Tc throughout the culture period (Tc+) or from OP9 cells did not contain detectable PU.1 protein. (E): Schematic diagram of culture systems in this study.

CTCAGA CC-3' and 5'-GACGATTCTCTTGACGCCAG-3'
Hprt: 5'-AGT TCT TTG CTG ACC TGC TG-3' and 5'-GCT
 TTGTATTTGGCTTTTCC-3'

Kdr (Flk-1): 5'-ACC GCC TCT GTG ACT TCT TT-
 3' and 5'-TGT CCC CTG CAA GTA ATC TG-3'

PCR was performed under the following conditions: an initial cycle consisting of 94°C for 4 minutes, annealing at 60°C for 3 minutes, and 72°C for 1 minute, followed by 34 cycles or 44 cycles of 94°C for 1 minute, annealing at 60°C for 1 minute, and 72°C for 1 minute. cDNA prepared from cells expressing each gene tested was used as a positive control (Posi). Distilled water (DW) was used for negative control.

Detection of Phagocytes

After ES cells were cultured on OP9 layers for 5 days in α MEM supplemented with 20% FBS (Thermo Trace), phagocytes were induced on pre-seeded ST2 layers for 6 days in α MEM supplemented with 10% FBS (Thermo Trace) and M-CSF. Cells were incubated with fluoresbrites microspheres (Polyscience, Niles, IL; <http://www.polyscience.com>) for 2 hours at 37°C. After washing, these cells were harvested by trypsinization. They were re-seeded into 100-mm culture dishes (Corning) to easily distinguish phagocytes from stromal cells. Under fluorescent microscopy, the number of phagocytes that had more than 20 fluorescent beads was counted. To observe appearances of phagocytes, the cells were recovered, cytopun, and stained with May-Grunwald-Giemsa solution.

Immunochemical Staining

Phagocytes were cultivated on cover glasses (Matsunami Glass Ind., Osaka, Japan; <http://www.matsunami-glass.co.jp/e>) and were incubated with latex beads (Sigma) for 2 hours at 37°C. After washing, cells were fixed with methanol for 15 minutes and then incubated with Blocking Ace (Snow Brand Milk Products, Co. Ltd., Tokyo, Japan; <http://www.snowbrand.co.jp>) for 20 minutes at 4°C. Macrosialin was detected with rat anti-mouse macrosialin antibody (FA11; Serotec, Raleigh, NC; <http://www.serotec.com>), biotinylated-goat anti-rat IgG antibody (KPL, Kirkegaard & Perry Laboratories, Gaithersburg, MD; <http://www.kpl.com>), streptavidin-peroxidase (KPL), and DAB reagent set (KPL).

RESULTS

Establishment of PU.1-Expressing *Tal1*^{-/-} ES Cell Lines under the Tc-off System

To provide a system for studying the regulated expression of PU.1, cDNA was placed under the control of the Tc-off system and introduced into *Tal1*^{-/-} ES cells (Fig. 1A). Three independent ES clones (designated TUNE-1 to TUNE-3)

were thereby established. Expression of the exogenous PU.1 was inhibited completely by 100 ng/ml Tc, and expression was induced by withdrawal of Tc from the culture. The expression of PU.1 was evaluated by monitoring the fluorescence of GFP (Fig. 1B, C). The expression of exogenous PU.1 reached a maximum level 1 day after Tc withdrawal (Fig. 1B). All three clones behaved similarly; therefore, representative data from TUNE-1 ES cells are shown unless otherwise indicated.

We used a stepwise culture system to induce osteoclasts from ES cells (Fig. 1E, osteoclast culture). PU.1 protein was detected on days 2 and 3 in PU.1-expressing (PU.1-on) TUNE ES cells in the osteoclast cultures but not in TUNE ES cells cultured in the presence of Tc (PU.1-off) or in OP9 cells (Fig. 1D).

Osteoclastogenesis from PU.1-Expressing TUNE ES Cells

Myelopoiesis and osteoclastogenesis are impaired in PU.1-null mice. To determine if exogenous PU.1 could rescue osteoclastogenesis in TUNE ES cells, TUNE ES cells were cultivated in osteoclast cultures. Multinucleated TRAP⁺ cells displaying more than six nuclei were induced from PU.1-on TUNE ES cells following Tc withdrawal on day 2 or 3 of culture. Although cells derived from TUNE ES cells existed, no TRAP⁺ cells were generated when Tc was present (Fig. 2A). This is consistent with our previous report that no TRAP⁺ cells were induced from *Tal1*^{-/-} ES cells [22]. PU.1 expression was restricted in GFP⁺ fraction (data not shown), and TRAP⁺ cells were mainly induced from GFP⁺ fraction. Non-specific toxicity of Tc could not account for these findings, as the number of TRAP⁺ cells derived from parental J1 ES cells was not affected by the presence of Tc.

To determine whether the TRAP⁺ cells were functional osteoclasts, a pit-formation assay was performed. On day 10 of the osteoclast culture, harvested cells were induced to form osteoclasts on dentine slices by co-culturing with ST2 cells supplemented with $1\alpha, 25(\text{OH})_2\text{D}_3$, Dex, human M-CSF, and human RANKL. On day 39, pit formation was observed in cultures of PU.1-on TUNE ES cells, whereas no pits were formed under the PU.1-off condition (Fig. 2A). These results indicate that mature functional osteoclasts were induced from *Tal1*^{-/-} ES cells following expression of PU.1.

M-CSF and RANKL are known to be critical for osteoclastogenesis. To investigate the requirement for these factors, an antagonistic anti-Fms antibody or a decoy receptor of RANKL, osteoprotegerin (OPG) [23] was added to the final phase of the osteoclast cultures on ST2 cells. Both factors completely inhibited osteoclastogenesis from PU.1-on TUNE ES cells (Fig. 2B). These results demonstrate that M-CSF and RANKL are also essential for the development of osteoclasts derived from PU.1-on TUNE ES cells.

Macrophage-Like Phagocytes Were Induced from PU.1-on TUNE Cells

PU.1 is an essential transcription factor for differentiation of macrophages. Since osteoclast precursors are thought to be derived from monocyte-lineage cells, it may be possible to induce monocyte and macrophage lineages by enforced expression of PU.1. Therefore, PU.1-on TUNE cells were cultivated on OP9 stromal layers for 5 days, then co-cultured with ST2 stromal cells supplemented with M-CSF for a further

6 days. Finally, these cells were incubated with fluorescent microspheres. Phagocytes that had more than 20 microspheres were counted under the fluorescent microscopy.

The numbers of phagocytes induced from TUNE-2 cells was one-fortieth compared with that from J1 wild type ES cells. Few cells with microspheres were observed in the cultures of *Tal1*^{-/-} J1 ES cells and PU.1-off TUNE-2 cells (Fig. 3A). These cells were cytopspun and stained with May-Grunwald-Giemsa solution to observe their appearances.




Figure 2. Enforced expression of PU.1-rescued osteoclastogenesis from *Tal1*^{-/-} ES cells. TUNE ES cells were cultured on OP9 cells for 10 days. Tc was withdrawn from day 2 (Tc-). The cells harvested on day 10 were induced to form osteoclasts on ST2. (A): Osteoclasts were induced in the schedule as described in Figure 1E (osteoclast culture). TRAP-positive cells were detected as red cells by TRAP staining (upper row). Osteoclasts were induced on dentine slices by co-culturing with ST2 in the presence of 1 α ,25(OH)₂D₃, Dex, M-CSF, and RANKL for a further 29 days. Pits are indicated by an arrowhead (lower row). Neither osteoclast nor pits was observed in the presence of Tc (Tc+). (B): After ES cells were cultivated on OP9 cells for 10 days, the cells harvested from cultures of parental wild-type J1 ES cells, or TUNE ES cells continuously treated with Tc (Tc) or from which Tc was withdrawn on day 2(-) were co-cultured on ST2 layers in the presence of 1 α ,25(OH)₂D₃ and Dex for 6 days. TUNE ES cells from which Tc had been withdrawn were cultured with an anti-Fms antagonistic antibody (Anti-Fms) or OPG during the final 6 days. Each column represents the mean \pm SD of triplicate cultures.




Figure 3. Macrophage-like phagocytes were induced from PU.1-on TUNE-2 cells. After ES cells were cultured on OP9 layers for 5 days, phagocytes were induced on ST2 layers supplemented with M-CSF for 6 days. Phagocytes with fluorescent beads (B) or nonfluorescent latex beads (C) were detected under microscopy. (A): The number of phagocytes was counted under fluorescent microscopy. J1: wild-type ES cells; *Tal1*^{-/-}: *Tal1*-deficient J1 ES cells. (B): Cytopspun cells were stained with May-Grunwald-Giemsa solution (upper row). Macrophage-like cells (arrowheads: upper row) with fluorescent microbeads (lower row). Tc-: cells cultured without Tc; Tc+: cells cultured with Tc. (C): Cells were stained with anti-macrosialin antibody. Macrosialin-positive cells were observed as brown. Isotype control: instead of anti-macrosialin antibody, anti-B220 antibody was used as the first antibody.

The bead-carrying cells from J1 ES and PU.1-on TUNE-2 cells looked like monocytes or macrophages (Fig. 3B). In contrast, almost all cells with microspheres in *Tal1*^{-/-} ES and PU.1-off TUNE-2 cell cultures were the feeder stromal cells (Fig. 3B).

To further clarify their phenotype, phagocytes were stained with the antibody directed to macrosialin, which is macrophage-restricted antigen [24]. Macrosialin was detected in phagocytes with latex beads from cultures of both wild-type J1 and PU.1-on TUNE cells, while no macrosialin-positive cells were detected in cultures of *Tal1*^{-/-} deficient ES cells. This is accordance with observation that no hematopoiesis occurs from *Tal1*^{-/-} ES. These results suggest that monocyte- and macrophage-like phagocytes were also induced from *Tal1*-deficient ES cells by enforced expression of PU.1.

Erythrocytes, Mast Cells, and Megakaryocytes Were Not Induced from TUNE-1 ES Cells

To assess whether other hematopoietic lineages might be rescued by the expression of PU.1, transcripts for several lineage-associated genes were examined by RT-PCR. ES cells were cultured on OP9 cell layers, and on day 5, cDNAs were synthesized from total RNA of cultured cells. Exogenous PU.1, but not endogenous PU.1, was expressed. Lineage-related genes (β -globin and ζ -globin for erythrocytes, mMC-CPA for mast cells, and platelet basic protein [PBP] for megakaryocytes) were analyzed. Transcripts for these markers were detected in cultures of wild-type J1 ES cells; none, however, were observed in PU.1-on TUNE ES cells



Figure 4. Several genes expressed in mast cells, erythrocytes, and megakaryocytes were not detected in PU.1-on TUNE-1 embryonic stem (ES) cells. After ES cells were cultured on OP9 cells for 5 days, mRNA was purified. The expression of several genes was analyzed by reverse transcription-polymerase chain reaction (RT-PCR). J1: cultured cells from wild-type J1 ES cell line; Tc+: TUNE ES cells cultured in the presence of tetracycline (Tc); Tc-: TUNE ES cells cultured with removal of Tc on day 2; OP9: stromal cells; Posi: positive controls.

(Fig. 4). These data indicate that exogenous PU.1 fails to rescue the development of mast cells, erythrocytes, and megakaryocytes in *Tal1*^{-/-} ES cells.

Gene Expression of the B-Cell Lineage Was Not Detected in the Hematopoiesis from TUNE ES Cells

PU.1 is considered essential for B lymphopoiesis [25]. To assess whether exogenous PU.1 expression was able to rescue B lymphopoiesis from TUNE ES cells, the ES cells were cultured on OP9 stromal cells for 8 days, and then re-cultured on ST2 cells for an additional 10 days. Flt3-ligand (20 ng/ml) and IL-7 (20 U/ml) were added to the cultures during days 5–8, and days 8–18, respectively (Fig. 1E) [26].

Clusters of small cells were observed in parental J1 ES cell cultures on day 18, but no clusters appeared in cultures of TUNE ES cells with or without Tc from day 2 (Fig. 5A). B-lineage-expressed genes were monitored by RT-PCR. *Pax5* and *Igb* were not expressed on cells from TUNE ES cells even in the absence of Tc, although these genes were detected in the cultured cells from wild-type J1 ES cells (Fig. 5B). These results indicate that B-lineage cells are not induced from *Tal1*^{-/-} ES cells with enforced expression of PU.1 under these culture conditions.




Figure 5. B-lymphocyte-related genes were not expressed in PU.1-on TUNE-1 embryonic stem (ES) cells. B-lineage cells were induced in the schedule as described in Figure 1E (B cell culture). (A): The appearance of each culture on day 18. (B): mRNA was prepared on day 18 of cultures, and the expressions of each gene were detected by reverse transcription-polymerase chain reaction (RT-PCR). J1: cultured cells from wild-type J1 ES cell line; Tc+: cells cultured in the presence of tetracycline (Tc); Tc-: cells cultured with removal of Tc on day 2; ST2: stromal cells; Posi: positive controls.

Efficiency of Osteoclastogenesis from *Tal1*^{-/-} ES Cells Depended on the Timing of the Expression of PU.1

Since the Tc-off system permits temporal regulation of PU.1 expression in TUNE ES cells, we examined the relationship between the efficiency of osteoclastogenesis and the timing of PU.1 expression. After switching the culture conditions to induce differentiation on OP9 cells, Tc was withdrawn from cultures of TUNE-1 and TUNE-2 ES cells on successive days. Withdrawal of Tc on days 0–4 allowed osteoclastogenesis to take place more efficiently than withdrawal after 6 days (Fig. 6A). No osteoclasts were induced in cultures of either ES clone subjected to the continuous exposure to Tc. Some variability in efficiency was observed in each experiment and clone, but the trend that day 2 to day 4 was the appropriate timing to express PU.1 for induction of TRAP⁺ cells from Tal-1-deficient ES cells was reproducible in all experiments and clones. These results indicate that the timing of expression of PU.1 is an important parameter in osteoclast induction, and day 2 to 4 is the appropriate timing. Since endogenous expression of PU.1 in cultures of undifferentiated wild-type J1 ES cells was first detected on day 5 rather than day 3 (data not shown), the timing of PU.1 expression for the rescue of osteoclastogenesis in *Tal1*^{-/-} ES cells preceded the normal pattern by 1–2 days.

Efficiency of osteoclastogenesis from TUNE cells was significantly lower than that from wild-type J1 ES cells. To determine whether this resulted from the low expression of PU.1, semi-quantitative RT-PCR was performed on day 5 of osteoclast culture. Expression of the *Kdr* (Flk-1) gene was used as the control of amount of ES cell-derived mRNA because frequency of Flk-1-expressing cells was not different among J1, PU.1-on, and PU.1-off TUNE cells, and Flk-1 was not expressed in OP9 stromal cells. Among three TUNE clones, TUNE-2 cells were the most efficiently differentiated to osteoclasts, but the efficiency was less than one-hundredth of that from wild-type ES cells. Interestingly, the expression of PU.1 was quantitatively not different from J1 cells (Fig. 6B). These results suggested that an adequate amount of expression of PU.1 was not enough to completely rescue osteoclastogenesis from *Tal1*^{-/-} ES cells.

Flk-1⁺ Cells Efficiently Differentiated to Osteoclasts by PU.1 Expression

Based on the results presented above, we hypothesized that hematogenic cells—for example, hemangioblasts and mesodermal cells immediately before their commitment to the hematopoietic cell lineage—might differentiate into osteoclasts with enforced expression of PU.1. Hematopoietic cells appear *in vivo* on embryonic day 7.5, whereas Kit⁺ blood cells are first observed on day 4 of ES cell culture [27]. At this

time, Flk-1⁺ cells containing hematopoietic precursors are present in ES cell cultures [28]. To assess the candidate cell populations with potential to differentiate into osteoclasts upon PU.1-expression, we compared the efficiency of osteoclastogenesis in Flk-1⁺ and Flk-1⁻ fractions.

J1 and TUNE ES cells were differentiated on OP9 cells. On day 3, Tc was withdrawn to allow for expression of PU.1. On day 4, the cells were harvested. No significant difference in the percentage of Flk-1⁺ cells on day 4 was observed in cells derived from wild-type versus TUNE ES cells, either in the PU.1-off or -on condition (Fig. 7A). We separated the harvested cells into the column-bound (positive) and -passed




Figure 6. Different efficiencies of osteoclastogenesis from *Tal1*^{-/-} ES cells depended on timing of expression of PU.1. (A): TUNE-1 and TUNE-2 ES cells were cultured in the schedule as described in Figure 1E, osteoclast culture. Shaded bars represent periods of addition of Tc. Each column represents the mean number \pm SD of TRAP-positive cells in triplicate cultures. (B): The amount of gene expression of *Sfp1* (PU.1) in TUNE-2 cells was not lower than that in cells derived from J1 ES cells. On day 5 of osteoclast culture, mRNA was purified, and semi-quantitative RT-PCR using sequential doses of cDNA (1, 1/2, 1/4) was performed. To estimate the amount of mRNA derived from ES cells, *Kdr* (Flk-1) RT-PCR products from serially doses of cDNA were indicated. Tc -: cells cultured without Tc; Tc +: cells cultured with Tc.

(negative) fractions by magnetic cell sorting using anti-Flk-1 antibody. The negative fraction contained 0% to 0.05% Flk-1⁺ cells (Fig. 7A). The fractionated cell populations were induced to form osteoclasts on ST2 cells supplemented with $1\alpha,25(\text{OH})_2\text{D}_3$ and Dex for 6 days. The number of TRAP⁺ cells from the positive fraction of J1 ES cells was increased >200-fold over the number from the negative fraction. In TUNE ES cells expressing PU.1 from day 3, TRAP⁺ cells developed from the positive fraction and not the negative fraction. Neither fraction of PU.1-off TUNE-1 ES cells generated TRAP⁺ cells (Fig. 7B). These results suggest that Flk-1⁺ cells on day 4 of osteoclast culture have the potential to differentiate to osteoclasts in response to PU.1 expression in the absence of Tal-1.




Figure 7. Flk-1⁺ cells included osteoclast precursors of PU.1-on TUNE-1 embryonic stem (ES) cells. After ES cells were cultivated on the OP9 layer for 4 days, the cells were harvested and subjected to magnetic sorting using Flk-1 antibody. (A): The proportion of Flk-1⁺ cells was analyzed by a flow cytometer. Negative: the column-passed fractions by the magnetic cell sorting using anti-Flk-1 antibody. Positive: the column-bound fraction. (B): Osteoclasts were induced from the sorted cells cultured on ST2 cells in the presence of $1\alpha,25(\text{OH})_2\text{D}_3$ and dexamethasone (Dex) for 6 days. Each column represents the mean numbers \pm SD of artrate-resistant acid phosphatase (TRAP)-positive cells in triplicate cultures. Tc: cells cultured in the presence of tetracycline (Tc).

DISCUSSION

Tal1 is essential for the development of all hematopoietic lineages and HSCs [1, 2]. The events downstream in the regulatory hierarchy from Tal-1 to specific lineages are largely unknown. Presumably, Tal-1 participates in the transcriptional control of critical downstream factors, perhaps including PU.1. In this study, we demonstrated that enforced PU.1 expression rescues osteoclastogenesis from *Tal1*^{-/-} ES cells, even though its efficiency was lower than that from J1 ES cells. These results suggest that PU.1 may serve as a critical factor for the osteoclast lineage. In addition, they raise the possibility that one role of Tal-1 may be to activate expression of PU.1 in a regulatory hierarchy. In these experiments, the expression of the endogenous *Sfp1* locus was not activated by exogenous PU.1 (Fig. 4). These observations suggest that PU.1 does not participate in a positive autoregulatory loop; they also indicate that the chromatin structure surrounding the endogenous *Sfp1* gene may be inaccessible before Tal-1 is expressed.

Macrophage-like phagocytes were also induced from PU.1-on TUNE cells. A small number of blood cell-like round cells appeared when PU.1-on TUNE cells were cultured in IL-3, GM-CSF, or G-CSF. These cells were cyto-spun and observed under microscopy. They looked like monocytes but not granulocytes (data not shown). We prefer the possibility that not only PU.1 but also other transcription factor(s) induced by Tal-1 were needed for granulopoiesis, even though we cannot rule out the possibility that it might be a result of the low sensitivity of granulocyte detection.

In our B-lymphoid culture system, the expression of B-cell-related genes was not detected from PU.1-expressing TUNE ES cells. As shown in Figure 5A, few, if any, hematopoietic-like cells were observed in PU.1-on TUNE ES cell cultures. Since GFP⁺ cells, indicative of ES cell derivatives (data not shown), and PU.1 transcripts were detected by RT-PCR (Fig. 5B), ES-derived cells were present, though unable to undergo B lymphopoiesis. *Pax5*-deficient mice have pro-B cells, and the *Igb* gene is detected [29]. Neither gene was expressed in PU.1-on TUNE ES cell cultures. Thus, the number of B cells generated might have been very small because of the failure of proliferation, or because B-lineage differentiation might need PU.1 and other transcription factor(s). We have not excluded the possibility that the level or timing of PU.1 expression may not have been suitable for B lymphopoiesis under our conditions (Tc withdrawal on day 2).

The efficiency of osteoclastogenesis of PU.1-on TUNE ES cells was significantly lower than that of wild-type ES cells. On culture day 5, the frequency of osteoclast precursors from wild-type ES cells was 1/2,485, while that from PU.1-on TUNE-1 ES cells was 1/1,389 to 1/39,063. We had

expected the low dosage of endogenous PU.1 compared with J1 ES cells might be responsible for the incomplete rescue of osteoclastogenesis. However, a comparable amount of PU.1 was detected in TUNE cells (Fig. 6B). This suggests that differentiation of osteoclasts was induced by PU.1, but orchestration of Tal-1 or other genes induced by Tal-1 was needed for efficient osteoclastogenesis.

We cannot rule out the possibility that the timing of the expression of PU.1 may be inappropriate. We showed in Figure 6 that the timing was critical for osteoclastogenesis from PU.1-on TUNE-1 and TUNE-2 ES cells. By regulating the time of expression of PU.1, we found that days 2–4 were most appropriate for rescue of osteoclastogenesis from *Tal1*-null ES cells. The efficiency of osteoclastogenesis by removal of Tc from day 0 was lower than that from day 2–4. This might show that exogenous PU.1 expression from initiation of cultures affected other than hematopoietic cell lineages. Moreover, according to the decline of osteoclastogenesis by removal of Tc after day 4, these cells might not be maintained in these cultures. Since mesodermal derivatives or hemangioblasts were thought to appear on day 4 of our culture system, they might be candidates of cells competent to differentiate into osteoclasts. These cells might exist in the richest on day 4 of all culture days. Since osteoclasts are of hematopoietic origin, we infer that PU.1 expression in *Tal1*-null ES cells bypasses a developmental block in a mesodermal derivative or hemangioblast. This interpretation is consistent with our finding that Flk-1⁺, rather than Flk-1⁻, cells are the source of osteoclasts generated upon PU.1 expression. The development of Flk-1⁺ cells in the absence of Tal-1 has been reported previously [30].

Tal-1 is indispensable for normal osteoclastogenesis

[22]. The results presented here raise the possibility that Tal-1 may act during a brief time interval to establish the hematopoietic program. Once it has activated critical downstream transcription factors, its role in the generation of selected lineages might be dispensable. This is consistent with the observation that Tal-1 is largely dispensable for maintenance of the adult hematopoietic system, once it has been established, except for differentiation of erythroid precursors and megakaryocytes [31]. Ectopic expression of transcription factors, such as illustrated here, may provide a means to define critical factors acting downstream of *Tal1* in the hematopoietic regulatory hierarchy.

ACKNOWLEDGMENTS

We acknowledge Dr. Tomohiro Kurosaki for his warm encouragement. We also thank Drs. Shin-Ichi Nishikawa (Riken) for anti-Fms and anti-Flk-1 antibodies; Hitoshi Niwa (Riken) and Richard Maki (Burnham Institute) for plasmids; Takao Taki and Masayuki Takahashi (Otsuka Pharmaceutical) for M-CSF; Tetsuo Sudo (Toray Industries) for GM-CSF and IL-3; Takumi Era (Riken) and Toru Nakano (Osaka University) for critical suggestions; Yasuhiko Nagasaka (Beckman Coulter K.K. Tokyo, Japan) for technical assistance of cell sorting by EPICS Elite; and Ms. Toshie Shinohara for her technical support. This work was supported by grants from Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology; from Research on Dementia and Fracture, Health and Labour Sciences Research Grants, the Japanese Government (S.I.H., H.Y.); and from the Molecular Medical Science Institute, Otsuka Pharmaceutical Co., Ltd. M.T. is a Research Fellow of the Japan Society for the Promotion of Science.

REFERENCES

- 1 Shivdasani RA, Mayer EL, Orkin SH. Absence of blood formation in mice lacking the T-cell leukemia oncogene *tal-1*/SCL. *Nature* 1995;373:432–434.
- 2 Porcher C, Swat W, Rockwell K et al. The T cell leukemia oncogene *SCL/tal-1* is essential for development of all hematopoietic lineage. *Cell* 1996;86:47–58.
- 3 Elefanty AG, Robb L, Birner R et al. Hematopoietic-specific genes are not induced during in vitro differentiation of *scl*-null embryonic stem cells. *Blood* 1997;90:1435–1447.
- 4 Dekoter RP, Walsh JC, Singh H. PU.1 regulates both cytokine-dependent proliferation and differentiation of granulocyte/macrophage progenitors. *EMBO J* 1998;17:4456–4468.
- 5 Dekoter RP, Lee HJ, Singh H. PU.1 regulates expression of the interleukin-7 receptor in lymphoid progenitors. *Immunity* 2002;16:297–309.
- 6 Scott EW, Simon MC, Anastasi J et al. Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages. *Science* 1994;265:1573–1577.
- 7 Tondravi MM, McKercher SR, Anderson K et al. Osteopetrosis in mice lacking hematopoietic transcription factor PU.1. *Nature* 1997;386:81–84.
- 8 Hayashi SI, Yamane T, Miyamoto A et al. Commitment and differentiation of stem cells to the osteoclast lineage. *Biochem Cell Biol* 1998;76:911–922.
- 9 Teitelbaum SL. Bone resorption by osteoclasts. *Science* 2000;289:1504–1508.
- 10 Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. *Nature* 2003;423:337–342.
- 11 Yoshida H, Hayashi SI, Kunisada T et al. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. *Nature* 1990;345:442–444.

- 12 Lacey DL, Timms E, Tan HL et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. *Cell* 1998;93:165–176.
- 13 Yasuda H, Shima N, Nakagawa N et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRNCE/RANKL. *Proc Natl Acad Sci U S A* 1998;95:3597–3602.
- 14 Kong YY, Yoshida H, Sarosi I et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. *Nature* 1999;397:315–323.
- 15 Yamane T, Kunisada T, Yamazaki H et al. Development of osteoclasts from embryonic stem cell through a pathway that is c-fms but not c-kit dependent. *Blood* 1997;90:3516–3523.
- 16 Yamane T, Kunisada T, Tsukamoto H et al. Wnt signaling regulates hemopoiesis through stromal cells. *J Immunol* 2001;167:765–772.
- 17 Yamada T, Yamazaki H, Yamane T et al. Regulation of osteoclast development by Notch signaling directed to osteoclast precursors and through stromal cells. *Blood* 2003;101:2227–2234.
- 18 Nishikawa SI, Ogawa M, Nishikawa S et al. B lymphopoiesis on stromal cell clone: stromal cell clones acting on different stages of B cell differentiation. *Eur J Immunol* 1988;18:1767–1771.
- 19 Nakano T, Kodama H, Honjo T. Generation of lymphohematopoietic cells from embryonic stem cells in culture. *Science* 1994;265:1098–1101.
- 20 Era T, Witte ON. Regulated expression of P210 Bcr-Abl during embryonic stem cell differentiation stimulates multipotential progenitor expansion and myeloid cell fate. *Proc Natl Acad Sci U S A* 2000;97:1737–1742.
- 21 Tsuneto M, Yamane T, Okuyama H et al. In vitro differentiation of mouse ES cells into hematopoietic, endothelial, and osteoblastic cell lineages: the possibility of in vitro organogenesis. *Methods Enzymol* 2003;365:98–114.
- 22 Yamane T, Kunisada T, Yamazaki H et al. Sequential requirements for SCL/tal-1, GATA-2, macrophage colony-stimulating factor, and osteoclast differentiation factor/osteoprotegerin ligand in osteoclast development. *Exp Hematol* 2000;7:833–840.
- 23 Simonet WS, Lacey DL, Dunstan CR et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. *Cell* 1997;89:309–319.
- 24 Rabinowitz SS, Gordon S. Macrosialin, a macrophage-restricted membrane sialoprotein differentially glycosylated in response to inflammatory stimuli. *J Exp Med* 1991;174:827–836.
- 25 Scott EW, Fisher RC, Olson MC et al. PU.1 functions in a cell-autonomous manner to control the differentiation of multipotential lymphoid-myeloid progenitors. *Immunity* 1997;6:437–447.
- 26 Cho SK, Webber TD, Carlyle JR et al. Functional characterization of B lymphocytes generated in vitro from embryonic stem cells. *Proc Natl Acad Sci U S A* 1999;96:9797–9802.
- 27 Hemmi H, Okuyama H, Yamane T et al. Temporal and spatial localization of osteoclasts in colonies from embryonic stem cells. *Biochem Biophys Res Commun* 2001;280:526–534.
- 28 Kabrun N, Buhring HJ, Choi K et al. Flk-1 expression defines a population of early embryonic hematopoietic precursors. *Development* 1997;124:2039–2048.
- 29 Nutt SL, Heavey B, Rolink AG et al. Commitment to the B-lymphoid lineage depends on the transcription factor Pax5. *Nature* 1999;401:556–562.
- 30 Faloon P, Arentson E, Kazarov A et al. Basic fibroblast growth factor positively regulates hematopoietic development. *Development* 2000;127:1931–1941.
- 31 Mikkola HKA, Klintman J, Yang H et al. Haematopoietic stem cells retain long-term repopulating activity and multipotency in the absence of stem-cell leukemia SCL/tal-1 gene. *Nature* 2003;421:547–551.

Lipopolysaccharide-Induced Osteoclastogenesis in Src Homology 2-Domain Phosphatase-1-Deficient Viable Motheaten Mice

SHIN-ICHI HAYASHI, MOTOKAZU TSUNETO, TAKAYUKI YAMADA, MICHINARI NOSE, MIYA YOSHINO, LEONARD D. SHULTZ, AND HIDETOSHI YAMAZAKI

Division of Immunology, Department of Molecular and Cellular Biology, School of Life Science (S.I.H., M.T., T.Y., M.N., M.Y., H.Y.); Division of Orthopedic Surgery, Department of Medicine of Sensory and Motor Organs (M.N.), Faculty of Medicine, Tottori University, and Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University Graduate School of Medical Science (H.Y.), Yonago, Tottori 683-8503, Japan; and The Jackson Laboratory (L.D.S.), Bar Harbor, Maine 04609

Osteoclasts are hemopoietic cells that participate in bone resorption and remodeling. Receptor activator of nuclear factor- κ B ligand (RANKL) and macrophage colony-stimulating factor (M-CSF) are critical for development of osteoclasts. The Toll-like receptor (TLR) family shares some of the downstream signaling with RANK. The TLR4 ligand, lipopolysaccharide (LPS), is reported to accelerate bone lysis; however, signaling via TLRs has never been reported to induce osteoclastogenesis without RANKL. In this study we showed that significant numbers of mature osteoclasts were generated from protein tyrosine phosphatase Src homology 2-domain phosphatase-1-defective *Hcph^{me-v}/Hcph^{me-v}* (*me^v/me^v*) bone marrow cells in the presence of M-CSF and LPS without addition of RANKL in culture. This M-CSF plus LPS-induced osteoclastogenesis was not inhibited by an anti-TNF α antagonistic antibody or by osteoprotegerin, a decoy receptor for

RANKL. The replacement of RANKL by TLR ligands only occurred with LPS. Other ligands, a peptidoglycan for TLR2 or an unmethylated CpG oligonucleotide for TLR9, did not support osteoclast generation. The osteoclast precursors as well as RANKL-responsive osteoclast precursors were present in the Kit-positive cell-enriched fraction of bone marrow cells. Although *me^v/me^v* bone marrow cells required a comparable concentration of RANKL or TNF α as wild-type cells for the initiation of osteoclastogenesis, the numbers of multinucleated osteoclasts in *me^v/me^v* bone marrow cultures were significantly increased by the equivalent dose of RANKL or TNF α in the presence of M-CSF. These results indicate that a defect of Src homology 2-domain phosphatase-1 function not only accelerates physiological osteoclast development by RANKL/RANK, but also acquires a novel pathway for osteoclastogenesis by LPS. (*Endocrinology* 145: 2721–2729, 2004)

SIGNALING VIA MACROPHAGE-colony-stimulating factor (M-CSF) and receptor activator of nuclear factor- κ B (NF- κ B) ligand (RANKL) plays an essential role for the development of osteoclast precursors (OCPs) into tartrate-resistant acid phosphatase (TRAP)-positive multinucleated cells (MNCs) that resorb and remodel bones (1–4). Functional M-CSF-deficient *Csf1^{op}/Csf1^{op}* (*op/op*) mice lack mature osteoclasts, resulting in severe osteopetrosis (5, 6). The *op/op* mice carrying the *Bcl2* transgene are cured of the disease, and aged *op/op* mice show spontaneous reversal of osteopetrosis (7, 8). Therefore, signaling through the M-CSF receptor (Fms) is thought to function as a cell survival signal, and vascular endothelial growth factor partially replaces its function (9). Viable

motheaten (*me^v/me^v*) mice mutated at the Src homology 2-domain phosphatase-1 (SHP-1) protein tyrosine phosphatase (*Hcph*) locus (10, 11) show accelerated osteoclastogenesis *in vitro* and *in vivo* (12, 13). Especially, numbers of TRAP⁺ MNCs were significantly increased (12, 13). In mice that are doubly homozygous for mutations at the *Csf1* and *Hcph* loci (*op/op me^v/me^v*) mice (12), partial, but significant, bone marrow (BM) formation was observed, indicating that the signaling via the receptor tyrosine kinases is regulated negatively by SHP-1 (10, 11).

RANK and its ligand, RANKL, are members of TNF receptor and TNF superfamilies, respectively (14, 15). Targeted mutation in either gene prevents the development of osteoclasts, resulting in the development of osteopetrosis (16, 17). Therefore, RANK/RANKL signaling is thought to be essential for osteoclastogenesis. However, several recent studies using RANK-knockout (RANK-KO) mice showed that osteoclastogenesis was induced without RANK/RANKL signaling (18, 19). Although it is still not clear whether RANK/RANKL signaling is totally absent (20), mouse TNF α was reported to induce osteoclastogenesis *in vivo* and *in vitro* in the presence of M-CSF (18, 21).

Signaling via members of the Toll-like receptor (TLR) superfamily shares some of the downstream pathways, such as TNF receptor-associated factor 6 (TRAF6), NF- κ B, and

Abbreviations: Ab, Antibody; BM, bone marrow; FBS, fetal bovine serum; Hpirt, hypoxanthine phosphoribosyl transferase; IRAK, IL-1 receptor-associated kinase; KO, knockout; LPS, lipopolysaccharide; M-CSF, macrophage-colony-stimulating factor; MNC, multinucleated cell; NF- κ B, nuclear factor- κ B; OCP, osteoclast precursor; ODN, oligonucleotide; OPG, osteoprotegerin; PE, phycoerythrin; PEC, peritoneal cavity cell; PGN, peptidoglycan; RANK, receptor activator of nuclear factor- κ B; RANKL, receptor activator of nuclear factor- κ B ligand; SHP, Src homology 2-domain phosphatase; TLR, Toll-like receptor; TRAF, TNF receptor-associated factor; TRAP, tartrate-resistant acid phosphatase; TREM, triggering receptor expressed on myeloid cell.

Endocrinology is published monthly by The Endocrine Society (<http://www.endo-society.org>), the foremost professional society serving the endocrine community.

MAPK, with RANK (22–24). Recently, SHP-1 was reported to interact with TRAF6 (25). Although lipopolysaccharide (LPS) is known to accelerate the bone lysis (26, 27) and promote the survival of osteoclasts (28), signaling via TLRs has never been reported to induce mature osteoclasts without RANKL (4). We reported that *in vivo* LPS injection increased the generation of BM osteoclast precursors, but the maturation from even these treated cells into TRAP⁺ cells required RANKL and M-CSF (29). Moreover, a cloned macrophage-like cell that lacks the *p53* gene differentiates into mature osteoclasts without M-CSF; however, RANKL is essential for its maturation (29–31). Therefore, signaling via TLRs may be insufficient as a substitute for RANK signaling.

In this study we showed that SHP-1 deficiency enabled BM cells treated with LPS plus M-CSF in the absence of RANKL to give rise to mature osteoclasts that resorb bone. The osteoclastogenesis does not depend on the production of RANKL or TNF α . These results indicate that SHP-1 regulates downstream signaling for osteoclastogenesis through not only receptor tyrosine kinases, but also members of the TNF receptor superfamily.

Materials and Methods

Mice

C57BL/6 (B6) mice were purchased from Japan-Clea (Yokohama, Japan). C57BL/6-*Hcph^{me-v}/Hcph^{me-v}* homozygotes (*me^v/me^v*) and their littermates (+/?) were raised at The Jackson Laboratory (Bar Harbor, ME). All mice were used at 7–16 wk of age.

Cell preparation and cultures

Mice were killed by cervical dislocation under ether anesthesia. BM cells were collected by flushing femoral shafts using a 26-gauge sterile needle. Cells from the peritoneal cavity (PECs) were obtained by injecting 4–8 ml ice-cold α MEM (Life Technologies, Inc., Grand Island, NY) supplemented with 10% fetal bovine serum (FBS; BioWhittaker, Walkersville, MD), 50 U/ml streptomycin, and 50 μ g/ml penicillin (Meiji Chemical Co. Ltd., Tokyo, Japan).

To induce osteoclast differentiation, BM cells ($1\text{--}2 \times 10^4$ /well) and PECs ($2\text{--}10 \times 10^4$ /well) were cultured in 24-well plates (Corning Costar, Corning, NY) with 1 ml α MEM-supplemented 10% FBS and antibiotics in the presence of 50 ng/ml human M-CSF (a gift from Otsuka Pharmaceutical Co. Ltd., Tokushima, Japan) and/or 25 or 50 ng/ml recombinant human soluble RANKL (PeproTech EC Ltd., London, UK), 50 ng/ml recombinant mouse TNF α (R&D Systems, Inc., Place, NE), or TLR ligands for 6 d. According to the manufacturer, RANKL was produced by *Escherichia coli*, but the endotoxin level in the RANKL is less than 0.1 ng/ μ g. Cultures were fed every 3 d by replacing spent medium with fresh medium.

The number of multinucleated TRAP⁺ cells (TRAP⁺ MNCs) was expressed as the mean \pm SD of triplicate cultures (32). In some experiments, 20 ng/ml recombinant human IL-1 α (a gift from Dr. S. Ono, Osaka University, Osaka, Japan) and 400 ng/ml human osteoprotegerin (OPG), a decoy receptor for RANKL (PeproTech EC Ltd.) were added to the cultures.

Pit formation assay

BM cells (5×10^3 /well) were cultured on dentine slices (a gift from Dr. N. Udagawa, Matsumoto Dental University, Nagano, Japan) in 0.2 ml α MEM containing 10% FBS and 50 ng/ml M-CSF with 50 ng/ml soluble RANKL or 50 ng/ml LPS for 20 d in 96-well plates. After removal of the cells with 2 N NaOH, the slices were stained with 2% Coomassie Brilliant Blue R250 in methanol to visualize resorption pits (14).

TLR ligands

LPS from *Salmonella minnesota* Re 595 (Sigma-Aldrich Corp., St. Louis, MO) or *E. coli* 055 B5 (Difco, Detroit, MI) were used for *in vitro* and *in vivo* experiments. As both LPS preparations induce similar responses, most experiments used *S. minnesota* R595 LPS unless otherwise indicated. Peptidoglycan (PGN) from *Staphylococcus aureus* (Fluka Chemie, Buchs, Switzerland), used to stimulate TLR2, was dissolved in water, sonicated, and sterilized in a hot water bath. A phosphorothioated oligonucleotide (ODN; 5'-TCC ATG ACG TTC CTG ATG CT-3'; CpG), used as an unmethylated CpG ODN to stimulate TLR9, and a control phosphorothioated ODN (5'-GCT TGA TGA CTC AGC CGG AA-3') were purchased from Hokkaido System Science (Hokkaido, Japan) (33).

Antibodies (Abs)

An antagonistic rat antimouse TNF α monoclonal Ab (XT3) was purchased from Endogen (Woburn, MA) and used at 5 μ g/ml for inhibition of TNF α activity. A nonantagonistic rat antimouse Kit Ab (ACK4) (34) was used as a control.

For flow cytometric analysis, monoclonal Abs against Fms (AF598, biotinylated) (35), Kit [ACK2, phycoerythrin (PE)-conjugated] (34), or Mac-1 (CD11b, FITC-conjugated; M1/70, BD Pharmingen, San Diego, CA) were used in Hanks' medium containing 2% BSA (fraction V, Sigma-Aldrich Corp.) and 0.05% NaN₃. The stained cells were analyzed using an EPICS-XL flow cytometer (Coulter Electronics, Hialeah, FL). Magnetic cell sorting for Kit-positive cell separation from BM cells was performed using the Mini-MACS column with PE-conjugated ACK2 and anti-PE antibody-conjugated microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany).

RT-PCR

To determine the expression of TNF α (encoded by *Tnf*), RANKL (*Tnfsf11*), IL-1 receptor-associated kinase (IRAK) (*Irak1*), IRAK-M (*Irak3*), and hypoxanthine phosphoribosyl transferase (*Hprt*) genes, RT-PCR was performed. Total RNA was isolated using Isogen (Nippon Gene, Toyama, Japan) and was reverse transcribed using Reverse TraAce (Toyobo, Osaka, Japan). The DNA fragments were amplified from the mouse cDNAs by PCR. Hot-lid PCR amplification of cDNA equivalent to 20, 2, and 0.2 ng total RNA was carried out in 1 \times PCR buffer (1.5 mM MgCl₂) containing 0.2 mM deoxy-NTPs (Takara, Shiga, Japan), 0.75 U *rTaq* DNA polymerase (Toyobo), and primers (used at 1.2 μ M). Amplifications were carried out on DNA thermal cyclers (MJ Research, Inc., Watertown, MA). After an initial 3-min denaturing step (94 C), each PCR cycle consisted of 45-sec denaturing (94 C), 1-min annealing (55 or 60 C), and 1.5-min elongation (72 C). After the final cycle, the reaction was held for 3 min at 72 C. The PCR products were then separated on a 2% agarose gel, stained with ethidium bromide, and photographed. The primers used here were as follows: *Tnf*, 5'-CAC GCT CTT CTG TCT ACT GAA CTT CG-3' and 5'-GGC TGG GTA GAG AAT GGA TGA ACA CC-3'; *Tnfsf11*, 5'-CAG CAC TCA CTG CTT TTA TAG AAT CC-3' and 5'-AGC TGA AGA TAG TCT GTA GGT ACG C-3'; *Irak1*, 5'-GCC AGT GGA AAG TGA TGA GAG TG-3' and 5'-GAA AAA GCC TGA TGA CAG CAG TTG-3'; *Irak3*, 5'-TCC TTC AGG TGT CCT TCT CCA CTG-3' and 5'-CCT CTT CTC CAT TGG CTT GCT C-3'; and *Hprt*, 5'-AAT GAT CAG TCA ACG GGG GAC A-3' and 5'-CCA GCA AGC TTG CA ACCT TAA CCA-3'.

MAPK inhibitors

Inhibitors of the MAPK signaling pathway, PD098059 (2'-amino-3'-methoxyflavone; Wako Pure Industry, Kyoto, Japan) for MAPK kinase (ERK1/2), SB203580 [4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)1H-imidazole; Wako] for p38, and SP600125 [anthrax(1-9-cd)pyrazol-6(2H)-one; Tocris Cookson Ltd., Avonmouth, UK] for c-Jun N-terminal kinase, were dissolved to 20 mM in dimethylsulfoxide and used at 20 μ M.

Statistical analysis

Data are presented as the mean \pm SD. Statistical significance was assessed by *t* test.

Results

LPS induces osteoclastogenesis from me^v/me^v BM cells

To induce osteoclastogenesis, BM cells from SHP-1-deficient me^v/me^v mice and their wild-type littermates (+/?) were cultured with M-CSF and RANKL for 6 d. me^v/me^v BM cells developed 1.5–4 times higher numbers of multinucleated TRAP⁺ cells (TRAP⁺ MNCs) than their +/? littermates (Fig. 1A, left) (12, 13). The TLR family shares some of the downstream signaling via RANK (22–24). However, signaling via TLRs has never been reported to induce osteoclastogenesis without RANKL-RANK signaling (4). We cultured BM cells from me^v/me^v and +/? littermates with LPS plus M-CSF for 6 d. Although TRAP⁺ mononuclear cells were generated, few TRAP⁺ MNCs were detected in the wild-type littermate cultures even in the presence of up to 200 ng/ml LPS (Fig. 1A, right, and Fig. 1B). In the presence of LPS and M-CSF, me^v/me^v BM cells gave rise to significantly higher numbers of TRAP⁺ mononuclear cells and TRAP⁺ MNCs than normal littermates (Fig. 1C). The number of TRAP⁺ MNCs induced by

LPS (20 ng/ml) and M-CSF was 1/10th to 1/3rd of those induced with RANKL (50 ng/ml) and M-CSF in me^v/me^v BM cultures (Fig. 1A, right). Osteoclastogenesis was increased in a dose-dependent manner for the LPS added (Fig. 1B). Osteoclasts from me^v/me^v BM cells induced by M-CSF and LPS had bone-resorbing activity on dentine slices, although the activity of pit formation was lower than that induced by M-CSF and RANKL (Fig. 1D).

One receptor for LPS activation is known to be a TLR4, a member of the TLR superfamily (36). To assess whether the inductive effect on osteoclastogenesis is specific for LPS-TLR4 signaling or is a general characteristic of signaling via TLR superfamily members, we examined the effects of ligands for other TLRs, PGN for TLR2 (37) and unmethylated CpG for TLR9 (33), on osteoclastogenesis in the presence of M-CSF. PGN or CpG showed little inductive effect on osteoclastogenesis in either me^v/me^v or +/? mice (Fig. 2A, left). As recently reported, CpG inhibited osteoclast development of BM cells from both me^v/me^v and +/? control mice induced by RANKL and M-CSF (Fig. 2A, right) (29, 38). This indicates that LPS, but not other TLR ligands tested here, induces osteoclastogenesis of SHP-1-deficient BM cells in the presence of M-CSF.

We also compared the effects of inhibitors of MAPK sig-




FIG. 1. Osteoclastogenesis of me^v/me^v BM cells induced by M-CSF and LPS. BM cells from me^v/me^v mice (■) and their wild-type littermates (+/?; □) were cultured with RANKL (A, left) or LPS in the presence of M-CSF for 6 d. LPS was added at 20 ng/ml (A, right; C and D), and varying doses (B; 0–200 ng/ml). A, Numbers of TRAP⁺ MNCs from three representative experiments. C, Numbers of total, mononuclear, and multinuclear TRAP⁺ cells. D, Photomicrographs of TRAP-stained cultures (d 6; magnification, $\times 100$) and pit formation on dentine slices (d 20; magnification, $\times 200$) of +/? (left) and me^v/me^v (right) BM cells. Significant differences compared with the responses of +/? littermates are indicated by an asterisk ($P < 0.05$). In all experiments, no TRAP⁺ cells were observed without M-CSF.




FIG. 2. LPS induces osteoclastogenesis from me^v/me^v BM cells. A, BM cells (2×10^4) from me^v/me^v mice (■) and their wild-type littermates (+/?; □) were cultured with or without 20 ng/ml LPS, 1 μ g/ml PGN, 0.1 μ M control ODN, or 0.1 μ M CpG-ODN in the presence of 50 ng/ml M-CSF (left) or M-CSF plus RANKL (right) for 6 d. B, BM cells cultured with or without 20 μ M MAPK inhibitors or the vehicle control dimethylsulfoxide (0.1%, vol/vol) in the presence of M-CSF and RANKL (left) or M-CSF and LPS (right) for 6 d. Significant differences compared with the responses of untreated cultures are indicated by an asterisk ($P < 0.05$). In all experiments, no TRAP⁺ cells were observed without M-CSF.

naling on RANKL- and LPS-induced osteoclastogenesis. Inhibitors (20 μ M) of the MAPK signaling pathway, PD098059 for MEK (ERK1/2), SB203580 for p38, and SP600125 for c-Jun N-terminal kinase, were added to the cultures for 6 d (Fig. 2B). SB203580 and SP600125 completely inhibited osteoclastogenesis in BM cells cultured with RANKL plus M-CSF and with LPS plus M-CSF. Although PD098059 did not completely inhibit osteoclastogenesis in either culture condition, this MAPK inhibitor reduced levels of osteoclastogenesis equivalently in these two culture system.

LPS-induced osteoclast development of me^v/me^v BM cells is not accounted for by the production of RANKL or TNF α

A recent report showed that TNF α mimicked the function of RANKL for stimulating *in vitro* osteoclastogenesis of BM cells (21). BM cells from me^v/me^v and $+/?$ mice were cultured with 50 ng/ml TNF α or 50 ng/ml RANKL in the presence of M-CSF for 6 d, and comparable numbers of osteoclasts in the cultures with TNF α or RANKL were observed in the BM cell cultures from each mouse strain (Fig. 3A). We also incubated the cultures with M-CSF and IL-1 α , but osteoclasts were not generated from either me^v/me^v or their littermate BM cells (Fig. 3A).

As LPS is known to induce TNF α production (28), we examined whether LPS-induced osteoclastogenesis was related to TNF α or RANKL production. If BM cells of me^v/me^v mice may produce high levels of TNF α or RANKL, osteoclastogenesis should occur in me^v/me^v BM cells. Therefore, BM cells from me^v/me^v and $+/?$ mice were cultured with M-CSF, or M-CSF plus LPS for 3 d. Although LPS addition increased the expression of the TNF α (*Tnf*) gene transcript and induced a small amount of transcript of the RANKL (*Tnfsf11*) gene, doses of transcripts of *Tnf* and *Tnfsf11* genes were comparable in both strains of mice (Fig. 3B).

Recently, Kobayashi *et al.* (36–39) reported that IRAK (encoded by *Irak1*) associated with MyD88 and IRAK-M (encoded by *Irak3*) regulate the signaling via TLRs. We assessed the expression of *Irak1* and *Irak3* in BM cells cultured with M-CSF or M-CSF plus LPS. *Irak3* gene expression was increased in the presence of LPS as reported; however, no significant difference was detected between me^v/me^v and $+/?$ cultured cells (Fig. 3B). An alternative possibility was that me^v/me^v BM cells may require a smaller amount of TNF α or RANKL to induce osteoclast development than wild-type BM cells, and LPS induces sufficient production of TNF α or RANKL to support osteoclastogenesis only in me^v/me^v BM cells. Thus, minimal requirements of TNF α or RANKL to induce TRAP $^+$ MNCs in cultures were assessed. More than 1 ng/ml TNF α or RANKL (Fig. 3C) was needed to induce osteoclastogenesis from both me^v/me^v and wild-type littermate BM cells.

To further confirm these observations, me^v/me^v BM cells were cultured with anti-TNF α antagonistic antibody (XT3) or OPG in the presence of M-CSF and LPS, and the inhibitory effect on LPS-induced osteoclastogenesis in me^v/me^v BM cells was observed. OPG and XT3 completely inhibited M-CSF and RANKL (50 ng/ml)-induced and M-CSF and TNF α




FIG. 3. Effects of LPS, TNF α , and IL-1 α on osteoclastogenesis. A, BM cells (2×10^4) from $+/?$ littermates (\square) or me^v/me^v mice (\blacksquare) were cultured with M-CSF and RANKL, 20 ng/ml LPS, TNF α , or IL-1 α for 6 d. The mean number and SD of TRAP $^+$ MNCs per well from the simultaneous experiments are shown. B, cDNA from BM cells of $+/?$ littermates and me^v/me^v mice cultured with M-CSF or M-CSF plus LPS for 3 d were prepared, and RT-PCRs for *Tnf*, *Tnfsf11*, *Irak1*, and *Irak3* were performed. Sequential doses of cDNA (equivalent to 20, 2, and 0.2 ng total RNA) were used as a template. Control responses were indicated by using primers for *Hprt*. C, Osteoclastogenesis induced by serial doses of RANKL (left) or TNF α (right) in the presence of M-CSF. In all experiments, no TRAP $^+$ cells were observed without M-CSF.

(50 ng/ml)-induced osteoclastogenesis, respectively; however, neither reagent inhibited M-CSF plus LPS-induced osteoclastogenesis (Fig. 4). Although less than 1 ng/ml RANKL or TNF α might be produced by BM cells in the cultures, these results suggest that SHP-1 regulates the magnitude of osteoclastogenesis, but not the minimal requirements of RANKL or TNF α , and indicate that osteoclast development by me^v/me^v BM cells induced by M-CSF plus LPS may not be directly related to the production of RANKL or TNF α .